Purpose: To evaluate outcomes of the Boston type I keratoprosthesis (KPro) and associated incidence of glaucoma.
T he Boston type I keratoprosthesis (KPro), approved for use by the Food and Drug Administration in 1992, was developed for patients who are poor candidates for traditional full-thickness corneal transplantation because of a high risk for graft failure or rejection. The indications for KPro implantation include recurrent corneal graft failure, herpetic disease, and limbal stem cell deficiency secondary to chemical burns and aniridia.
Initial KPro implantation was associated with poor outcomes related to implant extrusion, corneal necrosis, and endophthalmitis. 1 Because modifications in the implant design and postoperative management have evolved, the retention rates of the Boston type I KPro have dramatically improved, making the procedure an increasingly accepted alternative to standard keratoplasty in eyes with an unacceptably high risk of corneal graft failure. 2 With a reduction in acute complications, the long-term visual outcomes after KPro surgery are still limited by chronic diseases, such as glaucoma.
The purpose of this study was to review the clinical experience at 1 institution using the Boston type I KPro and to evaluate the development and progression of glaucoma after KPro surgery in these patients.
SUBJECTS AND METHODS
A retrospective chart review was conducted of all KPro surgeries performed between October 2003 and June 2009 at the W.K. Kellogg Eye Center, University of Michigan, by a single surgeon (S.I.M.) with a minimum follow-up of 3 months. Patients with less than 3 months of follow-up were excluded to improve the assessment of subacute and chronic changes in intraocular pressure (IOP) after surgery. Study approval was granted by the Institutional Review Board.
The Boston type I KPro, obtained from the Massachusetts Eye and Ear Infirmary (Boston, MA), was used in all eyes. Inclusion criteria for surgery included vision worse or equal to 20/200, a reasonable blink or tear film, a history of 2 or more penetrating keratoplasty (PKP) failures or poor candidacy for keratolimbal allograft surgery, no evidence of significant retinal disease or end-stage optic nerve cupping, and intact nasal light projection. Patients with less than 3 months of follow-up were excluded from the study.
Patients were evaluated preoperatively by a member of the glaucoma service faculty (J.S.W., J.D.S., S.E.M., and D.J.) to assess the need for preoperative or concomitant glaucoma surgery, which included endoscopic or transscleral diode cyclophotocoagulation, Ahmed FP-7 glaucoma drainage device implantation (New World Medical, Rancho Cucamonga, CA), and 350-mm 2 Baerveldt glaucoma drainage device implantation (Advanced Medical Optics, Inc, Santa Ana, CA).
All phakic patients underwent extracapsular cataract extraction at the time of the KPro procedure. Pars plana vitrectomy was performed when the glaucoma drainage device was placed in the pars plana. Aphakic KPro implants were used in eyes with crystalline lens extraction, anterior chamber intraocular lens implant removal, and preoperative aphakia. Pseudophakic KPros were used in eyes with stable, previously implanted, posterior chamber, intraocular lenses.
KPro implantation was performed using a standard technique. 3 A Kontur soft contact lens (Kontur Kontact Lens, Richmond, CA) was placed either at the end of surgery or on the first postoperative day. Postoperatively, all patients were started on prednisolone acetate 1%, topical vancomycin (25 mg/mL), and either topical moxifloxacin 0.5% or gatifloxacin 0.3% 4 times per day each in the operated eye. The vancomycin was continued for at least 6 months postoperatively. Topical or oral glaucoma medications were added or additional glaucoma surgery was performed based on clinical findings of increased IOP by digital palpation (when compared with the IOP in the contralateral eye that was assessed by Goldmann applanation), optic nerve head appearance, or worsening visual fields [Humphrey (Carl Zeiss Ophthalmic Systems, Dublin, CA) or Goldmann].
Data collected regarding preoperative characteristics included demographics, indication for surgery, previous ocular surgeries, preoperative ocular and medical comorbidities (glaucoma, diabetes mellitus, hypertension and smoking status), best-corrected visual acuity (BCVA), IOP and, if available, optic nerve status. Intraoperative characteristics recorded included surgery time, type of KPro (aphakic vs. pseudophakic and threadless vs. threaded), donor and host trephine size, front and back plate size, concomitant surgeries at time of KPro implantation, and intraoperative complications. Postoperative data included BCVA, tactile IOP, optic nerve appearance, retinal evaluation, topical and oral medications, anatomic retention of the KPro, and postoperative surgeries or procedures. When IOP was recorded as a range in the chart (eg, 10-15 mm Hg), the median value of the range was used for statistical analysis. Data were collected postoperatively at intervals of 1 day, 1 week, 1 month, 3 months, 6 months, 9 months, 1 year, and then annually.
Elevated IOP was defined as 22 mm Hg or higher when measured by digital palpation, which required the addition of topical or oral glaucoma therapy. Glaucoma development or progression of preexisting disease was defined as elevated IOP associated with glaucomatous optic nerve head changes, glaucomatous visual field changes, or the need for subsequent glaucoma surgical intervention.
Descriptive and comparative analyses of the data were performed using SAS 9.2 statistical software (SAS Institute, Cary, NC). Comparisons of mean values made use of the independent 2-tailed t test, and comparisons of categorical data made use of Fisher exact test. For all analyses, P # 0.05 was considered statistically significant.
RESULTS
Thirty-three eyes of 32 patients underwent Boston type I KPro surgery between October 2003 and June 2009. Three of these eyes were excluded from the analysis in this study because of the follow-up of less than 3 months. Mean (6SD) follow-up was 17 6 19 months (range, 3-67 months). There were 16 men (55%) and 13 women (45%). The KPro implants were implanted in 11 right eyes (37%) and 19 left eyes (63%). The mean age at surgery was 59 years (range, 21-88 years; SD, 20 years). Six eyes (20%) underwent repeat KPro implantation.
Twenty-three eyes (77%) had a history of failed PKP, with an average of 2.2 previous PKPs per eye (range, 1-5; SD, 1.2). Seven eyes (23%) underwent KPro surgery without previous PKP. Four of these eyes had chemical burns, 2 had aniridia, and 1 had a history of herpetic keratitis ( Table 1) .
The median preoperative BCVA was hand motions (range, 20/200 to light perception). Visual acuity was light perception with projection in 3 eyes (10%), hand motions in 16 eyes (53%), counting fingers in 8 eyes (27%), 20/400 in 1 eye (3%), and 20/200 in 2 eyes (7%). Preoperatively, 20 eyes (67%) had a previous diagnosis of glaucoma, with 8 of the 20 eyes (40%) having undergone incisional glaucoma surgery before KPro implantation, including 3 with glaucoma drainage devices, 3 with transscleral diode cyclophotocoagulation, and 2 with a trabeculectomy. Before KPro implantation, the average number of glaucoma medications (topical or oral) in these 20 patients was 2.4 (range, 0-5; SD, 1.1). The mean preoperative IOP for all 30 patients was 15.8 mm Hg (range, 5-35; SD, 6.8). The mean IOP for eyes with a previous diagnosis of glaucoma was 17.0 mm Hg (range, 5-35; SD, 7.5), and for eyes without a diagnosis of glaucoma, it was 13.5 mm Hg (range, 7-21; SD, 4.4). The mean cup-to-disc ratio was 0.55 (range, 0.4-0.9; SD, 0.24) in the 4 patients who could be assessed preoperatively.
Of the 30 eyes that underwent KPro implantation, 22 (73%) received an aphakic KPro and 8 (27%) received a pseudophakic KPro. Twenty-one eyes (70%) underwent concomitant glaucoma surgery, which included glaucoma drainage device implantation in 14 eyes (6 Ahmed and 8 Baerveldt glaucoma drainage devices) and endocyclophotocoagulation in 7 eyes. Seven patients (23%) underwent concomitant cataract extraction, and 6 patients (20%) required pseudophakic intraocular lens removal. Three of the 14 eyes (21%) with concomitant glaucoma drainage device implantation also underwent concomitant pars plana vitrectomy to facilitate placement of the glaucoma drainage device tube into the vitreous cavity. Three of the 11 eyes (27%) that had concomitant glaucoma drainage device implantation with insertion of the tube into the anterior chamber were noted to have occluded tubes postoperatively necessitating subsequent pars plana vitrectomy and repositioning of the tube into the vitreous cavity.
The mean BCVA postoperatively was 20/510 at 3 months (range, 20/20 to no light perception; N = 30), 20/550 at 6 months (range, 20/20 to no light perception; N = 23), 20/330 at 9 months (range, 20/20 to hand motions; N = 18), and 20/390 at 1 year (range, 20/40 to light perception; N = 16). The BCVA at the last follow-up for all patients was 20/600 (range, 20/40 to no light perception). When comparing preoperative BCVA with final BCVA, vision improved in 19 of 30 eyes (63%) and was unchanged in 7 eyes (23%). Vision worsened in 4 eyes (13%) because of glaucoma in 3 eyes, 2 of which became no light perception, and retinal detachment occurred in 1 eye ( Fig. 1) .
Postoperative elevation in IOP (22 mm Hg or higher) that required the addition of topical or oral glaucoma medications was noted in 15 eyes (50%). These 15 eyes had a mean preoperative IOP of 13.7 mm Hg, a mean postoperative IOP of 29.5 mm Hg (range, 22.5-35; SD, 4.0) before initiation of treatment, and a mean postoperative IOP of 9.5 mm Hg at the last follow-up after the addition of glaucoma therapy. There was a trend toward an increase in the number of glaucoma medications postoperatively compared with preoperatively (1.8 postoperative when compared with 1.1 preoperative). In the 15 eyes that did not have elevated IOP develop, the mean preoperative IOP was 18.0 mm Hg and the mean postoperative IOP at the last follow-up was 12.8 mm Hg. There was also a trend toward a decrease in the number of glaucoma medications postoperatively as compared with preoperatively (0.7 postoperative when compared with 2.1 preoperative). In the 15 eyes that had postoperative elevated IOP develop, 14 (93%) had no previous glaucoma surgery and 1 had previous transscleral diode cyclophotocoagulation, whereas 7 of the 15 eyes (47%) that did not have elevated IOP postoperatively had glaucoma surgery before KPro implantation (P = 0.04) ( Table 2) .
Glaucoma development or progression was noted in 7 of the 15 eyes (23% of total eyes) that had postoperative elevated IOP. Glaucoma developed in 2 of the 10 eyes (20%) without a previous history of glaucoma and progressed in 5 of the 20 eyes (25%) with a previous diagnosis of glaucoma. Of the 7 eyes with glaucoma development or progression, only 1 had glaucoma surgery before KPro implantation. Five of these 7 eyes, including the 1 with previous glaucoma surgery, underwent concomitant glaucoma surgery. Postoperatively, 6 of these 7 eyes required further surgical intervention. This included a Baerveldt drainage device implantation in an eye that had no previous or concomitant glaucoma surgery, transscleral diode cyclophotocoagulation in 2 eyes, and pars plana vitrectomy with tube revision to the pars plana in 3 eyes. The mean IOP at the last follow-up in the 7 eyes that had glaucoma develop or had glaucomatous progression was 21.0 mm Hg compared with 14.3 mm Hg in eyes that did not have glaucoma develop ( Table 2 ). The mean visual acuity at the last follow-up of those eyes that had glaucoma development or progression was 3/200 when compared with 20/563 in the remaining 23 eyes (P = 0.51). All 7 eyes were noted to have glaucomatous optic nerve head changes during their postoperative course. The mean cup-to-disc ratio in these 7 eyes was 0.83 (range, 0.5-1.0; SD, 0.19) at either the 1-month or the 3-month visit and 0.93 (range, 0.7-1.0; SD, 0.11) at 1 year postoperatively. There was no statistically significant difference in preoperative corneal diagnoses between the eyes that had glaucoma develop or an elevation in IOP when compared with eyes without elevation in IOP or glaucoma development or progression.
COMPLICATIONS
No significant intraoperative complications occurred. In 1 eye, a limited suprachoroidal hemorrhage developed postoperatively within 1 week of surgery and spontaneously cleared over the next 2 months. Two patients (7%) required retinal detachment repair, and no patients had vitritis or infectious endophthalmitis develop.
Six patients (20%) required repeat KPro implantation. KPro implants without titanium locking rings had been placed in the first 2 eyes and were subsequently replaced within 1 to 4 months in both the cases because of dislocation. Corneal stromal necrosis developed in 4 eyes (13%), requiring replacement of the KPro implants 4 to 12 months after initial surgery. All 4 patients had inflammatory corneal disease with a history of chemical burn (3 of 4) and Mooren ulcer (1 of 4). Retroprosthetic membranes (RPM) developed postoperatively in 23 eyes (77%). Fourteen of these 23 eyes (61%) underwent an Nd:YAG laser membranotomy, and 1 eye (4%) underwent pars plana pupillary membranectomy ( Table 3 ). The following cases illustrate development and progression of glaucoma after Boston type I KPro surgery.
Case 1
N.M. was a 25-year-old woman with an ocular history significant for aniridia and poorly controlled secondary glaucoma of both eyes. At presentation, her visual acuity was 
Case 2
H.F. was a 74-year-old woman with an ocular history significant for pseudophakic bullous keratopathy of the left eye status-post 2 failed full thickness PKPS performed in 1999 and 2003. Because of her poor prognosis for a third PKP, a decision was made to implant a Boston type I KPro. She had no preoperative history of glaucoma. On examination, her BCVA was counting fingers. Her preoperative IOP was 13 mm Hg, and she had a healthy-appearing optic nerve with a cup-to-disc ratio of 0.4. She underwent uncomplicated KPro implantation with concomitant anterior chamber intraocular lens removal in December 2005. Postoperatively, her acuity improved to 20/25 3 months after surgery and remained stable for more than 1 year. Her IOP ranged between 15 and 20 mm Hg, and her cup-to-disc ratio ranged between 0.4 and 0.5. On a routine follow-up visit in November 2006, she was noted to have an IOP between 20 and 25 mm Hg. Her acuity remained 20/25, and her cup-to-disc ratio was 0.5. She was started on timolol 0.5%. Three months later, her vision had declined to 20/70, the IOP was in the 30s, and her optic nerve was noted to have significantly increased cupping.
She underwent urgent pars plana vitrectomy with insertion of a
Baerveldt glaucoma drainage device in February 2007. Postoperatively, her vision stabilized at 20/70 with IOP ranging between 10 and 15 mm Hg on timolol 0.5%. At this point, her cup-to-disc ratio was greater than 0.9. Despite IOP in the low teens with a functional Baerveldt drainage device and close follow-up by both the cornea and the glaucoma services over the next year, her visual acuity declined from 20/80 to hand motions by April 2008 as a result of glaucomatous progression. Her vision has remained unchanged as of January 2010.
DISCUSSION
Our results indicate that patients undergoing KPro surgery with adequate control of IOP through either medical or surgical intervention during the perioperative period fared better than those without. In patients with a preoperative diagnosis of glaucoma and aggressive preoperative IOP control who underwent KPro implantation, the mean postoperative IOP was lower and there were fewer glaucoma medications added postoperatively. The eyes that had previous glaucoma surgery were less likely to experience glaucoma progression or elevated IOP after KPro implantation when compared with those that did not.
Glaucoma is already a prevalent disease in this patient population and is likely multifactorial in pathogenesis. In eyes with chemical burns, the prevalence of glaucoma has been reported to be between 22% and 55%. 4, 5 In aniridic eyes, glaucoma incidence has been reported between 6% and 75%, with a prevalence as high as 91%. 5, 6 In eyes that have undergone standard PKP, the incidence of glaucoma has been reported to vary between 9% and 31% in the early postoperative period and from 18% to 35% in the late postoperative period. 7 Glaucoma management is especially challenging in eyes that have undergone KPro implantation for several reasons. First, evaluations of the optic nerve and visual fields are usually difficult preoperatively because of corneal opacification. In addition, tonometers are inaccurate over a Boston KPro, and digital palpation is currently the closest available assessment of IOP. 2 There is significant need for methods to be developed to accurately measure IOP after KPro implantation. Another challenge in monitoring these patients is that they often have comorbid eye diseases, including advanced glaucoma, retinal detachment, and macular ischemia, which limit their ability to perform visual field testing. According to our results, KPro implantation alone can increase the risk for glaucoma development or progression. We postulate that the mechanism of increased IOP in KPro eyes is multifactorial, including gradual closure of the angle from peripheral anterior synechiae, abrupt blockage of the angle from the KPro device itself, inflammation, bleeding, and vitreous debris. 8 Netland et al 1 reported performing a total iridectomy during KPro implantation in an attempt to prevent secondary angle closure glaucoma; however, the prevalence of glaucoma postoperatively was still 58% in that series, indicating that other mechanisms likely played a role in glaucoma development.
One complication observed in our patient population that underwent combined surgery with a glaucoma drainage device implanted into the anterior chamber was unintentional occlusion of the tube, which required tube revision surgeries in 5 eyes. If the tube is placed in the anterior chamber, then retaining a stable previously placed posterior chamber intraocular lens implant may help prevent vitreous from occluding the tube. Ciliary sulcus placement of a tube shunt is difficult because of the presence of a unicameral chamber or anterior chamber crowding in pseudophakic eyes with the KPro implant design (anterior-posterior stem length of 2.7 mm). Pars plana tube insertion into the vitreous cavity may be a viable alternative that can offer potential advantages over anterior chamber insertion. Though it requires previous or concurrent pars plana vitrectomy, a pars plana tube insertion can avoid occlusion secondary to anterior segment crowding or to vitreous and iris plugging. If pars plana vitrectomy and glaucoma drainage device placement are performed subsequent to KPro implantation, then the vitrectomy also offers the ability to clear any vitreous opacities or RPM that may be obstructing vision. 9 Another challenge in the management of patients undergoing KPro implantation is determining which eyes are at risk for an acute elevation of IOP and which are at risk for late glaucoma development, as exemplified in cases 1 and 2. Therefore, aggressive control of IOP is warranted, including surgical intervention in all patients undergoing KPro surgery. Although larger nonvalved glaucoma drainage devices may offer better long-term IOP control than valved devices, they require intentional occlusion for several weeks postoperatively to avoid early hypotony. 10 Thus, patients may be at risk for glaucoma progression in the immediate postoperative period if their IOP cannot be controlled by medical management or venting slits while the tube is still intentionally occluded. Careful assessment of a patient's glaucoma status preoperatively is imperative. Eyes at risk for vision loss developing from increased IOP during the immediate postoperative period may require use of a flow-restrictive device or placement of a glaucoma drainage device before KPro implantation. Endoscopic or transcleral diode cyclophotocoagulation may be preferred in the setting of conjunctival cicatricial disease or when previously placed glaucoma drainage devices are not adequately functioning.
A significant complication in our study that affected postoperative visual acuity results was RPM formation. Twenty-three eyes (77%) were found to have RPM, which is higher than previously reported rates of 26% to 65%. 2, [11] [12] [13] This may be associated with predisposing chronic inflammatory conditions in these eyes. There were no cases of endophthalmitis or sterile vitritis compared with previous reports of 0% to 11% and 0% to 10%, respectively. This may be because of the use of topical antibiotic therapy with both vancomycin and a fluoroquinolone for a period of at least 6 months (Table 3) .
Although previously reported rates have been low (2%-13.5%), our series indicates that postoperative glaucoma is a significant disease to contend with in this patient population 2, [11] [12] [13] (Table 3 ). Some of the limitations of our study include its retroprospective design, small sample size, limited follow-up for some eyes, reliance on digital palpation to measure IOP, and difficulty assessing optic nerve status and visual fields because of media opacities.
Because implantation of the Boston type I KPro becomes a more widely accepted alternative to standard keratoplasty surgery in patients at high risk because of improved outcomes and retention rates, glaucoma may be increasingly seen as a significant cause of visual loss, including blindness. Aggressive perioperative management of glaucoma, including preoperative and concomitant glaucoma surgery, may help prevent the development or progression of glaucoma and improve visual outcomes in these challenging patients.
